Benefits and harms of perioperative high fraction inspired oxygen for surgical site infection prevention: a protocol for a systematic review and meta-analysis of individual patient data of randomised controlled trials

Research output: Contribution to journalJournal articleResearchpeer-review

Documents

  • Fulltext

    Final published version, 478 KB, PDF document

  • Stijn W. de Jonge
  • Rick H. Hulskes
  • Maedeh Zokaei Nikoo
  • Robert P. Weenink
  • Kate Leslie
  • Paul Myles
  • Andrew Forbes
  • Robert Greif
  • Ozan Akca
  • Andrea Kurz
  • Daniel I. Sessler
  • Janet Martin
  • Marcel G.W. Dijkgraaf
  • Kane Pryor
  • F. Javier Belda
  • Carlos Ferrando
  • Gabriel M. Gurman
  • Christina M. Scifres
  • David S. McKenna
  • Matthew T.V. Chan
  • Pascal Thibon
  • Jannicke Mellin-Olsen
  • Benedetta Allegranzi
  • Marja Boermeester
  • Markus W. Hollmann

Introduction The use of high fraction of inspired oxygen (FiO2) intraoperatively for the prevention of surgical site infection (SSI) remains controversial. Promising results of early randomised controlled trials (RCT) have been replicated with varying success and subsequent meta-analysis are equivocal. Recent advancements in perioperative care, including the increased use of laparoscopic surgery and pneumoperitoneum and shifts in fluid and temperature management, can affect peripheral oxygen delivery and may explain the inconsistency in reproducibility. However, the published data provides insufficient detail on the participant level to test these hypotheses. The purpose of this individual participant data meta-analysis is to assess the described benefits and harms of intraoperative high FiO2compared with regular (0.21–0.40) FiO2 and its potential effect modifiers. Methods and analysis Two reviewers will search medical databases and online trial registries, including MEDLINE, Embase, CENTRAL, CINAHL, ClinicalTrials. gov and WHO regional databases, for randomised and quasi-RCT comparing the effect of intraoperative high FiO2 (0.60–1.00) to regular FiO2 (0.21–0.40) on SSI within 90 days after surgery in adult patients. Secondary outcome will be all-cause mortality within the longest available follow-up. Investigators of the identified trials will be invited to collaborate. Data will be analysed with the one-step approach using the generalised linear mixed model framework and the statistical model appropriate for the type of outcome being analysed (logistic and cox regression, respectively), with a random treatment effect term to account for the clustering of patients within studies. The bias will be assessed using the Cochrane risk-of-bias tool for randomised trials V.2 and the certainty of evidence using Grading of Recommendations, Assessment, Development and Evaluation methodology. Prespecified subgroup analyses include use of mechanical ventilation, nitrous oxide, preoperative antibiotic prophylaxis, temperature (<35°C), fluid supplementation (<15 mL/kg/hour) and procedure duration (>2.5 hour). Ethics and dissemination Ethics approval is not required. Investigators will deidentify individual participant data before it is shared. The results will be submitted to a peer-review journal.

Original languageEnglish
Article numbere067243
JournalBMJ Open
Volume13
Issue number10
Number of pages8
ISSN2044-6055
DOIs
Publication statusPublished - 2023

Bibliographical note

Funding Information:
SWdJ reports receipt of grants from Photonics in Healthcare, Integra LifeSciences and Ethicon outside the submitted. PM reports receipt of grants or contracts from the Australian National Health and Medical Research Council (NHMRC), Practitioner Fellowship and Projects Grants, payment of expert testimony from Avant Medical Indemnity, and participation on a Data Safety Monitoring Board of Advisory Board for the SNAP, TOPIC-2 and BONANZA trials. AF reports receipt of institutional grants from the Australian Research Council Discovery Project and National Health and Medical Research Council Ideas outside the submitted work and participation on a Data Safety Monitoring Board or Advisory Board for the Australian Kidney Trials Research Network (INCH-HD, IMPEDE, TEQCH-PD, PHOSPHATE, BEST Fluids, N3RO trial, CKD-FIX, IMPROVE-FIX). RG reports participation on Steering Committee for the IntuBot Innosuisse Projekt and has a leadership role as ERC Director of Guidelines and ILCOR, and ILCOR Task Force Chair on Education, Implementation and Team, and Treasurer of European Airway Management society, and reports receipt without any payment of airway equipment for the research of the following: Intersurgical, Karl Storz, Verathon, Aircraft Medical, Prodol Meditec, Venner Medical, Kingsystems, Medtronic, Ambu, VBM, Radiometer, Sentec and Fisher & Paykel. AK reports receipt of grants or contracts from Potrero Medical, Rehabtronics and The 37Company outside the submitted work and participation on a Data Safety Monitoring Board of Advisory Board in Directed systems, Potrero Medical and BioAgel Laboratories. JM-O reports voluntary participation as a panellist in the updated WHO Guidelines on high versus low FiO2 in 2018 and voluntary coinvestigator in the PENGUIN trial of high versus low FiO2 for SSI prevention in abdominal surgery in low-income and middle-income settings with GlobalSurg Collaborative. MGWD reports participation on a Data Safety Monitoring Board or Advisory Board for the following trials: DANCE, SPHINX, ICONIC, SAFE, PACER, LEARNS, RECAP and BIOPEX2. CF reports receipt fees for lectures and educational events from Getinge and Medtronic outside the submitted work. CMS reports receipts of institutional grants from NICHD outside the submitted work. MB reports receipt of institutional grants from KCI/3M, Johnson & Johnson, New Compliance, BD Bard, Gore, Telabio, GDM, Medtronic and Smith & Nephew outside the submitted work, and participation on the Data Monitoring Committee of the EXTEND trial. MWH reports receipt of institutional grants from ZonMw outside the submitted work, consulting institutional fees from IDD Pharma outside the submitted work, institutional payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from CSL Behring outside the submitted work and has a leadership role in DGAI, ISAP and IARS (Anaesthesia and Analgesia). The other authors declare no conflict of interest.

Funding Information:
This work was supported by the Amsterdams Universiteitsfonds grant (4069) to RHH.

Publisher Copyright:
© World Health Organization 2023.

ID: 396098851